Tags

Type your tag names separated by a space and hit enter

Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial.
Am J Geriatr Psychiatry. 2006 Sep; 14(9):767-76.AJ

Abstract

OBJECTIVES

The objectives of this study were to evaluate the efficacy, safety, and tolerability of quetiapine for treating psychosis in patients with probable/possible Alzheimer disease and assess its impact on other psychopathology and social and daily functioning.

METHOD

The authors conducted a multicenter, double-blind, placebo-controlled, randomized trial of flexibly dosed quetiapine and haloperidol. Primary outcomes were change in total Brief Psychiatric Rating Scale (BPRS) and Clinical Global Impressions-Severity of Illness (CGI-S) scores at week 10. Secondary outcomes included BPRS factors, Neuropsychiatric Inventory (NPI), Multidimensional Observation Scale for Elderly Subjects (MOSES), and Physical Self-Maintenance Scale (PSMS).

RESULTS

Two hundred eighty-four participants (mean age: 83.2 years) were randomized; 63.4% completed; and mean Mini-Mental State Examination score was 12.8. Median of the mean daily dose was 96.9 mg for quetiapine and 1.9 mg for haloperidol. No differential benefit was seen on any psychosis measure. BPRS agitation factor scores improved with quetiapine versus placebo and not quetiapine versus haloperidol. BPRS anergia scores worsened with haloperidol versus quetiapine but not quetiapine versus placebo. No NPI factors showed change, including the agitation factor. MOSES Withdrawal Subscale and PSMS total scores worsened with haloperidol versus quetiapine. Somnolence occurred in 25.3%, 36.2%, and 4.1% of the quetiapine, haloperidol, and placebo groups, respectively; parkinsonism was most prevalent in the haloperidol group; other safety and tolerability measures differed little among groups.

CONCLUSION

All treatment groups showed improvement in measures of psychosis without significant differences between them when planned comparisons were performed. Participants treated with quetiapine or haloperidol showed inconsistent evidence of improvement in agitation. Tolerability was better with quetiapine compared with haloperidol.

Authors+Show Affiliations

Memory Disorders Center, Banner Alzheimer's Disease Institute, Phoenix, Arizona, USA. pierre.tariot@bannerhealth.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16905684

Citation

Tariot, Pierre N., et al. "Quetiapine Treatment of Psychosis Associated With Dementia: a Double-blind, Randomized, Placebo-controlled Clinical Trial." The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry, vol. 14, no. 9, 2006, pp. 767-76.
Tariot PN, Schneider L, Katz IR, et al. Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. Am J Geriatr Psychiatry. 2006;14(9):767-76.
Tariot, P. N., Schneider, L., Katz, I. R., Mintzer, J. E., Street, J., Copenhaver, M., & Williams-Hughes, C. (2006). Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry, 14(9), 767-76.
Tariot PN, et al. Quetiapine Treatment of Psychosis Associated With Dementia: a Double-blind, Randomized, Placebo-controlled Clinical Trial. Am J Geriatr Psychiatry. 2006;14(9):767-76. PubMed PMID: 16905684.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. AU - Tariot,Pierre N, AU - Schneider,Lon, AU - Katz,Ira R, AU - Mintzer,Jacobo E, AU - Street,Jamie, AU - Copenhaver,Margaret, AU - Williams-Hughes,Celeste, Y1 - 2006/08/11/ PY - 2006/8/15/pubmed PY - 2007/1/4/medline PY - 2006/8/15/entrez SP - 767 EP - 76 JF - The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry JO - Am J Geriatr Psychiatry VL - 14 IS - 9 N2 - OBJECTIVES: The objectives of this study were to evaluate the efficacy, safety, and tolerability of quetiapine for treating psychosis in patients with probable/possible Alzheimer disease and assess its impact on other psychopathology and social and daily functioning. METHOD: The authors conducted a multicenter, double-blind, placebo-controlled, randomized trial of flexibly dosed quetiapine and haloperidol. Primary outcomes were change in total Brief Psychiatric Rating Scale (BPRS) and Clinical Global Impressions-Severity of Illness (CGI-S) scores at week 10. Secondary outcomes included BPRS factors, Neuropsychiatric Inventory (NPI), Multidimensional Observation Scale for Elderly Subjects (MOSES), and Physical Self-Maintenance Scale (PSMS). RESULTS: Two hundred eighty-four participants (mean age: 83.2 years) were randomized; 63.4% completed; and mean Mini-Mental State Examination score was 12.8. Median of the mean daily dose was 96.9 mg for quetiapine and 1.9 mg for haloperidol. No differential benefit was seen on any psychosis measure. BPRS agitation factor scores improved with quetiapine versus placebo and not quetiapine versus haloperidol. BPRS anergia scores worsened with haloperidol versus quetiapine but not quetiapine versus placebo. No NPI factors showed change, including the agitation factor. MOSES Withdrawal Subscale and PSMS total scores worsened with haloperidol versus quetiapine. Somnolence occurred in 25.3%, 36.2%, and 4.1% of the quetiapine, haloperidol, and placebo groups, respectively; parkinsonism was most prevalent in the haloperidol group; other safety and tolerability measures differed little among groups. CONCLUSION: All treatment groups showed improvement in measures of psychosis without significant differences between them when planned comparisons were performed. Participants treated with quetiapine or haloperidol showed inconsistent evidence of improvement in agitation. Tolerability was better with quetiapine compared with haloperidol. SN - 1064-7481 UR - https://www.unboundmedicine.com/medline/citation/16905684/Quetiapine_treatment_of_psychosis_associated_with_dementia:_a_double_blind_randomized_placebo_controlled_clinical_trial_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1064-7481(12)60711-8 DB - PRIME DP - Unbound Medicine ER -